Meeting
2021 ASCO Annual Meeting
GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).
Authors
Jaume Mora
Pediatric Surgery Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
Jaume Mora , Mariona Suñol , Nadia Hindi , Alicia Castañeda , Andrés Redondo , Francisco José Bautista Sirvent , Robert Diaz Beveridge , Antonio Lopez-Pousa , Jose A. Lopez-Martin , Javier Martin Broto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
2016-002464-14
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11529)
DOI
10.1200/JCO.2021.39.15_suppl.11529
Abstract #
11529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
First Author: Gertjan VAN HAL
Poster
2017 ASCO Annual Meeting
ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study.
First Author: Kara L. Davis
Poster
2017 ASCO Annual Meeting
A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
First Author: Rachel J. Cook